SG11201809753YA - Reagents for treatment of hepatitis b virus (hbv) infection and use thereof - Google Patents

Reagents for treatment of hepatitis b virus (hbv) infection and use thereof

Info

Publication number
SG11201809753YA
SG11201809753YA SG11201809753YA SG11201809753YA SG11201809753YA SG 11201809753Y A SG11201809753Y A SG 11201809753YA SG 11201809753Y A SG11201809753Y A SG 11201809753YA SG 11201809753Y A SG11201809753Y A SG 11201809753YA SG 11201809753Y A SG11201809753Y A SG 11201809753YA
Authority
SG
Singapore
Prior art keywords
hbv
international
promoters
reagents
hepatitis
Prior art date
Application number
SG11201809753YA
Other languages
English (en)
Inventor
Tin Mao
David Suhy
Original Assignee
Benitec Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benitec Biopharma Ltd filed Critical Benitec Biopharma Ltd
Publication of SG11201809753YA publication Critical patent/SG11201809753YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201809753YA 2016-05-05 2017-05-05 Reagents for treatment of hepatitis b virus (hbv) infection and use thereof SG11201809753YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332245P 2016-05-05 2016-05-05
PCT/AU2017/050413 WO2017190197A1 (en) 2016-05-05 2017-05-05 Reagents for treatment of hepatitis b virus (hbv) infection and use thereof

Publications (1)

Publication Number Publication Date
SG11201809753YA true SG11201809753YA (en) 2018-12-28

Family

ID=60202535

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809753YA SG11201809753YA (en) 2016-05-05 2017-05-05 Reagents for treatment of hepatitis b virus (hbv) infection and use thereof

Country Status (11)

Country Link
US (2) US11535851B2 (ru)
EP (1) EP3452595A4 (ru)
JP (1) JP2019514401A (ru)
KR (1) KR102358280B1 (ru)
CN (1) CN109415733A (ru)
AU (2) AU2017260580B2 (ru)
CA (1) CA3023185A1 (ru)
PH (1) PH12018502320A1 (ru)
RU (2) RU2748806C2 (ru)
SG (1) SG11201809753YA (ru)
WO (1) WO2017190197A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2748806C2 (ru) * 2016-05-05 2021-05-31 Бенитек Байофарма Лимитед Средства для лечения инфекции вируса гепатита в (hbv) и их применение
JP7441174B2 (ja) * 2018-11-16 2024-02-29 公益財団法人東京都医学総合研究所 Ｂ型肝炎ウイルスの複製阻害組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
RU2217161C2 (ru) * 1997-08-26 2003-11-27 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) Способ лечения вирусного гепатита
WO2003006477A1 (en) * 2001-07-12 2003-01-23 University Of Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
CN1257284C (zh) 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
US8575327B2 (en) * 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
DE602005027747D1 (de) 2004-12-22 2011-06-09 Alnylam Pharmaceuticals Inc Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
WO2008147430A2 (en) 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
CN101603042B (zh) 2008-06-13 2013-05-01 厦门大学 可用于乙型肝炎病毒感染治疗的rna干扰靶点
US20120142764A1 (en) * 2009-06-05 2012-06-07 Dai-Wu Seol Multi-Cistronic shRNA Expression Cassette for Suppressing Single or Multiple Target Genes
US20130267429A1 (en) * 2009-12-21 2013-10-10 Lawrence Livermore National Security, Llc Biological sample target classification, detection and selection methods, and related arrays and oligonucleotide probes
KR101903778B1 (ko) * 2010-10-28 2018-10-04 베니텍 바이오파마 리미티드 Hbv 치료
US8809293B2 (en) * 2011-06-30 2014-08-19 Arrowhead Madison Inc. Compositions and methods for inhibiting gene expression of hepatitis B virus
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
HRP20220607T1 (hr) * 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
WO2014117050A2 (en) 2013-01-26 2014-07-31 Mirimus, Inc. Modified mirna as a scaffold for shrna
CN103088026A (zh) 2013-02-01 2013-05-08 中国人民解放军军事医学科学院放射与辐射医学研究所 抗乙型肝炎病毒人工miRNA及其组合
PL243776B1 (pl) * 2013-09-02 2023-10-09 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Cząsteczka kwasu nukleinowego, kaseta ekspresyjna, wektor ekspresyjny, komórka eukariotycznego gospodarza i zastosowanie cząsteczki kwasu nukleinowego w terapii chorób wywoływanych ekspansją trójnukleotydowych powtórzeń typu CAG
CN107683336A (zh) 2015-05-06 2018-02-09 贝尼泰克生物制药有限公司 用于治疗乙型肝炎病毒(hbv)感染的试剂及其用途
RU2748806C2 (ru) * 2016-05-05 2021-05-31 Бенитек Байофарма Лимитед Средства для лечения инфекции вируса гепатита в (hbv) и их применение

Also Published As

Publication number Publication date
AU2022241489A1 (en) 2022-10-20
RU2021113126A (ru) 2021-08-20
KR20190003756A (ko) 2019-01-09
US20230093951A1 (en) 2023-03-30
RU2018142797A3 (ru) 2020-09-10
RU2018142797A (ru) 2020-06-05
EP3452595A4 (en) 2020-02-19
CN109415733A (zh) 2019-03-01
US11535851B2 (en) 2022-12-27
CA3023185A1 (en) 2017-11-09
KR102358280B1 (ko) 2022-02-07
WO2017190197A1 (en) 2017-11-09
JP2019514401A (ja) 2019-06-06
US20190338285A1 (en) 2019-11-07
RU2748806C2 (ru) 2021-05-31
AU2017260580B2 (en) 2022-07-28
PH12018502320A1 (en) 2022-01-24
EP3452595A1 (en) 2019-03-13
AU2017260580A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201805001UA (en) Method of treating influenza a
SG11201810179RA (en) Novel crispr enzymes and systems
SG11201906795SA (en) Novel plant cells, plants, and seeds
SG11201810048VA (en) Tri-segmented pichinde viruses as vaccine vectors
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201806340YA (en) Zika virus vaccine
SG11201808314QA (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
SG11201903483VA (en) Compositions and methods for treating ezh2-mediated cancer
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201808306PA (en) Treatment of cancer with tg02
SG11201809594WA (en) Nicotine particles and compositions
SG11201903042VA (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201810333UA (en) Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders